Digestive tract pathology

Sebastiano Biondo Aglio

PRINCIPAL INVESTIGATORS
  • Ricardo Frago Montanuy
  • Jordi Guardiola Capon
  • Josep Maria Botargues Bote
  • Marta Climent Agusti
  • Alexandra Ruiz Cerulla
CLINICAL RESEARCHERS
  • Jaime Lopez Borao
  • Kristel Mils Julià
  • Ana Roberta Galvez Saldaña
  • Carla Bettonica Larrañaga
  • Claudia Arajol González
  • Zoilo Madrazo González
  • Ana Maria Berrozpe López
  • Thomas Golda
  • Loris Trenti
SCIENTIFIC SUPPORT
  • Oriana Carolina Barrios Cormenzanza
  • Blau Camps Aler
Translational Medicine
Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention

Scientific production

26

PAPERS

Average IF: 7,74

11

LED PAPERS

Average IF: 3,94

4 PUBLICATIONS IN FIRST DECILE

10 PUBLICATIONS IN FIRST QUARTILE

15 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Serra Aracil,X;Pericay,C;Badia Closa,J;Golda,T;Biondo,S;Hernández,P;Tarragona,E et al, Short-term outcomes of chemoradiotherapy and local excision vs total mesorectal excision in T2-T3ab,N0,M0 rectal cancer. A multicentre randomised, controlled, phase III trial (the TAUTEM study)., Ann. Oncol., 2023;34(1):78-90, doi:10.1016/j.annonc.2022.09.160
  • Fundora,Y;Hessheimer,AJ;Del Prete,L;Maroni,L;Lanari,J;Barrios,O;Clarysse,M et al, Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis, J. Hepatol., 2023;78(4):794-804, doi:10.1016/j.jhep.2023.01.007
  • Correa Bonito,A;Cerdán Santacruz,C;Di Martino,M;Blanco Terés,L;Gancedo Quintana,Á;Martín Pérez,E;Biondo,S et al, Treatment for acute uncomplicated diverticulitis without antibiotherapy: systematic review and meta-analysis of randomized clinical trials., Int. J. Surg., 2023;109(5):1412-1419, doi:10.1097/JS9.0000000000000307
  • Chaparro,M;Acosta,D;Rodriguez,C;Mesonero,F;Vicuna,M;Barreiro de Acosta,M;Fernandez Clotet,A et al, Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety, Am. J. Gastroenterol., 2023;118(7):1237-1247, doi:10.14309/ajg.0000000000002145
  • Serrano,I;Luque,A;Ruiz Cerulla,A;Navas,S;Blom,AM;de Córdoba,SR;Fernández,FJ et al, C4BP(ß-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients, Pharmacol. Res., 2023;197106948-106948, doi:10.1016/j.phrs.2023.106948

Research highlights

PROJECTS

1 Granted competitive project
7 Ongoing competitive projects

19 Ongoing clinical trials
Started non competitive project
1 Ongoing non competitive project

INNOVATION

1 Patent
1 License

Selected projects

  • 18ACL129. AN OBSERVATIONAL PROSPECTIVE LONG-TERM EXPOSURE REGISTRY OF ADJULT PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS. ICON Clinical Research UK No2 limited. Budget: 186.800€. 2018- . PI: Guardiola Capón, Jordi.
  • 14ACL125. REGISTRO NO INTERVENCIONISTA DE LARGA DURACIÓN PARA EVALUAR LA SEGURIDAD Y LA EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES CON COLITIS ULCEROSA (CU) DE ACTIVIDAD MODERADA A GRAVE (LEGACY). MAPI SAS. Budget: 94.640€. 2014- . PI: Guardiola Capón, Jordi.
  • 18ACL053. ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN’S DISEASE. Budget: 76.000€. 2018-2024. PI: Guardiola Capón, Jordi.
  • 19ACL036. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de crohn que respondan al tratamiento de inducción en los estudios M16-006, M15-991 o que hayan completado el estudio M15-989. Abbvie Biotherapeutics Inc. Budget: 40.722€. 2019- . PI: Guardiola Capón, Jordi.
  • PUB22004. Estudio prospectivo y multicéntrico sobre factores clínico-biológicos predictivos de Diverticulitis CRÓnica de colon (DICRO). Hospital Universitario de Bellvitge. Budget: 19.450€. 2022-2025. PI: Climent Agustín, Marta.